Synonyms 原癌基因蛋白质c-bcl-2, Apoptosis regulator Bcl-2, B-cell CLL/lymphoma 2 + [6] |
Introduction Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells (PubMed:1508712, PubMed:8183370). Regulates cell death by controlling the mitochondrial membrane permeability (PubMed:11368354). Appears to function in a feedback loop system with caspases (PubMed:11368354). Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PubMed:11368354). Also acts as an inhibitor of autophagy: interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function (PubMed:18570871, PubMed:21358617, PubMed:20889974). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785). |
Target |
Mechanism Bcl-2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date11 Apr 2016 |
Target |
Mechanism Bcl-2 inhibitors [+3] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date01 Jan 1997 |
Target |
Mechanism Bcl-2 inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date31 Aug 2024 |
Sponsor / Collaborator |
Start Date16 Aug 2024 |
Sponsor / Collaborator |